Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18032097 | 0.91 | SPHK1 (0.42) | SPHK1SPHK2 | |
| SCHEMBL18252140 | 0.84 | SPHK1 (0.46) | SPHK1SPHK2 | |
| SCHEMBL12624263 | 0.84 | SPHK1 (0.46) | SPHK1SPHK2 | |
| SCHEMBL12622673 | 0.83 | GRM2 (0.33) | CYP2C9 | |
| SCHEMBL12622667 | 0.83 | OPRL1 (0.34) | — | |
| SCHEMBL12622386 | 0.82 | GRM2 (0.34) | — | |
| SCHEMBL18251932 | 0.82 | FFAR4 (0.34) | — | |
| SCHEMBL12622773 | 0.81 | OPRL1 (0.35) | — | |
| SCHEMBL12622882 | 0.81 | OPRL1 (0.35) | — | |
| SCHEMBL18251914 | 0.81 | SPHK1 (0.42) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777219-B2 | Liquid crystal compound having tetracycle, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777219-B2 | Liquid crystal compound having tetracycle, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160340584-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRACYCLE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160340584-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRACYCLE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340584-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRACYCLE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, CALCOCO2, ZKSCAN2 | SPHK1 3033/4885SPHK2 2802/4885CYP2C9 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.